MeiraGTx Announces FDA Breakthrough Therapy Designation and Reports 2025 Financial Results

Key Highlights

• FDA Breakthrough Therapy Designation: MeiraGTx received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for treating Grade 2 and Grade 3 late radiation-induced xerostomia (RIX) in patients with cancers of the upper aerodigestive tract.
• Upcoming Program Update: The company will present a program update and 3-year data for AAV2-hAQP1 on April 16, 2026, including commercial opportunities.
• Strategic Collaborations: Two major collaborations executed in 2025:
  • Eli Lilly & Company: Collaboration focused on AAV-AIPL1 for LCA4 and two preclinical ocular programs, intravitreal capsids, bespoke promoters, and riboswitch platform rights. MeiraGTx received a \$75M upfront payment and is eligible for over \$400M in milestones and tiered royalties.
  • Hologen Limited: Joint venture formed for AAV-GAD in Parkinson’s disease, with a \$200M upfront payment and up to \$230M committed funding. MeiraGTx holds 30% ownership and leads clinical development and manufacturing.
• Riboswitch Platform Progress: Preparing first Riboswitch IND for Ribo-leptin (metabolic disease), with promising preclinical data and discussions ongoing with FDA. Second riboswitch program targeting neuropathic pain is showing encouraging data.
• Ophthalmology Program Developments:
  • Botaretigene Sparoparvovec (bota-vec): Positive Phase 3 LUMEOS trial data for X-linked Retinitis Pigmentosa (XLRP) presented, with FDA Fast Track and Orphan Drug designations, EU PRIME and ATMP designations. MeiraGTx eligible for \$285M in milestones upon first commercial sales and manufacturing tech transfer. Commercial supply agreement with Johnson & Johnson Innovative Medicine completed.
• Financial Position: Cash and cash equivalents at \$65.9M as of December 31, 2025, with additional receivables and committed capital from collaborations expected to fund operations into the second half of 2027.

Detailed Financial Results (2025 vs. 2024)

• Cash, Cash Equivalents and Restricted Cash: \$68.2M (2025) vs. \$105.7M (2024).
• Service Revenue: \$6.4M (2025) vs. \$33.3M (2024) – decrease due to completion of PPQ services for Johnson & Johnson.
• License Revenue: \$75.0M (2025) – from Lilly collaboration; none in 2024.
• Cost of Service Revenue: \$4.8M (2025) vs. \$23.8M (2024).
• General and Administrative Expenses: \$52.9M (2025) vs. \$54.2M (2024).
• Research and Development Expenses: \$129.6M (2025) vs. \$119.5M (2024) – increase due to higher manufacturing and preclinical activity.
• Foreign Currency Gain: \$2.1M (2025) vs. loss of \$2.9M (2024).
• Interest Income: \$1.8M (2025) vs. \$4.1M (2024).
• Interest Expense: \$12.2M (2025) vs. \$13.3M (2024).
• Net Loss: \$114.2M (2025), (\$1.42 per share), improved from \$147.8M (2024), (\$2.12 per share).
• Shareholder Equity: Swung to a deficit of \$5.8M (2025) from positive \$67.8M (2024).

Operational and Clinical Pipeline Updates

AAV2-hAQP1 for Radiation-Induced Xerostomia

• Breakthrough Therapy and RMAT designations from FDA.
• Phase 2 AQUAx2 study aligned with FDA requirements; final patients enrolling with potential BLA filing in H1 2027 and US launch targeted early 2028.
• 3-year data from Phase 1 to be presented April 16, 2026.

AAV-GAD for Parkinson’s Disease

• RMAT designation granted for patients not adequately controlled with medication.
• Statistically significant efficacy observed in multiple clinical studies.
• Pivotal Phase 3 study expected to initiate in coming months, fully funded by Hologen Neuro AI joint venture.
• Hologen AI’s generative models used to de-risk clinical datasets and identify disease-modifying effects.

Ophthalmology Programs

• Strategic collaboration with Eli Lilly for AAV-AIPL1 and gene therapy tech, with significant upfront and milestone payments, plus tiered royalties.
• Botaretigene sparoparvovec (bota-vec) Phase 3 results for XLRP showed remarkable patient benefit; strong regulatory support in US/EU; commercial supply agreement with J&J completed.
• MeiraGTx eligible for substantial milestone payments on successful commercialization and manufacturing tech transfers.

Riboswitch Platform

• Riboswitch technology enables precise, dose-responsive gene expression control via oral small molecules.
• First IND for Ribo-leptin in metabolic disease expected to open this year; animal data demonstrates durability out to 19 months.
• Second riboswitch program targeting neuropathic pain with promising preclinical data.
• Platform has broad applicability for proteins, peptides, and hormones – AI-driven discovery underway.

Capital and Liquidity

• Cash position enhanced by upfront payments from Lilly (\$75M), Hologen (\$200M + up to \$230M), and additional receivables.
• Expected funding runway into second half of 2027, including ability to repay \$25M debt in June 2026 and \$50M in May 2027.
• Potential for additional cash inflow: \$135M from Lilly and \$285M from J&J upon milestones and asset sales.

Shareholder Considerations & Potential Price-Sensitive Information

• Breakthrough Therapy Designation: AAV2-hAQP1’s FDA designation and positive long-term data could accelerate regulatory approval and commercialization, representing a significant value inflection point.
• Strategic Collaborations: Major upfront payments and milestone-based agreements with Eli Lilly and Hologen provide non-dilutive funding and de-risk pipeline programs, improving financial stability and upside potential.
• J&J Partnership for XLRP: Completion of Phase 3 trial and commercial supply agreement, with strong regulatory support, could lead to substantial milestone payments and royalties.
• Riboswitch Platform Progress: Advancement toward first IND and robust preclinical data open new therapeutic markets and may drive investor interest.
• Financial Improvement: Reduced net loss, improved cash position, and clear funding runway are positive for shareholders, though equity has swung to a deficit, which warrants attention.
• Upcoming Milestones: Potential near-term catalysts include Phase 3 initiations, regulatory filings, commercial launches, and additional payments from partners.

Disclaimer

This article is provided for informational purposes only and does not constitute investment advice. Forward-looking statements herein are based on management’s current expectations and subject to risks, uncertainties, and other factors that may cause actual results to differ materially. Investors should review MeiraGTx’s filings with the SEC and consult their financial advisor before making any investment decisions.

View MeiraGTx Holdings plc Historical chart here